☆ 4.2 Letter

The correlation of CD70 in immune characteristics and drug therapy of pan-cancer

HUMAN CELL (2023)

Related references

Note: Only part of the references are listed.
Review Oncology

The CD70-CD27 axis in oncology: the new kids on the block

Tal Flieswasser et al.

Summary: The CD70-CD27 axis has been found to play a role in tumor progression and immune suppression, while also participating in co-stimulation in immune responses under normal physiological conditions. In hematological malignancies, co-expression of CD70 and CD27 promotes the stemness, proliferation, and survival of cancer cells. In solid tumors, CD70 expression facilitates immune evasion through CD27 expression in the tumor microenvironment. The CD70-CD27 axis has emerged as a novel target for oncology research and (pre)clinical therapeutic strategies.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2022)

Add to Collection
Article Oncology

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment

Mathieu Seyfrid et al.

Summary: This study identifies CD70 as a potential therapeutic target for recurrent glioblastoma stem cells (CSCs). Targeting CD70 with CAR-T therapy significantly improves prognosis in animal models and the CD70/CD27 axis may provide a viable polytherapeutic avenue for targeting both glioblastoma and its tumor immune microenvironment.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection
Article Multidisciplinary Sciences

TNF plays a crucial role in inflammation by signaling via T cell TNFR2

Muhammad S. Alam et al.

Summary: The study revealed that TNF can induce the differentiation of mouse CD4(+) T cells into proinflammatory Th17 cells, mediated by the nondeath TNF receptor TNFR2, and also has an impact on the generation of proinflammatory Th1 cells. Additionally, TNFR2-deficient CD4(+) T cells showed lower pathogenicity in EAE and colitis.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Add to Collection
Article Oncology

CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer

Mayu Shiomi et al.

Summary: This study aimed to investigate the cytotoxicity of a CD70-ADC against ovarian cancer in in vitro and in vivo models. Results showed that CD70-ADC was cytotoxic to ovarian cancer cells expressing CD70 and could potentially be used in the treatment of CD70 expressing ovarian cancer.

CANCER SCIENCE (2021)

Add to Collection
Review Biochemistry & Molecular Biology

Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches

Punit Saraon et al.

Summary: Receptor tyrosine kinases play a significant role in cancer and have been a major class for targeted therapeutics. However, current treatments often lead to acquired resistance. New technologies are being developed to identify novel RTK small molecule therapeutics.

ONCOGENE (2021)

Add to Collection
Article Biochemistry & Molecular Biology

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Carsten Riether et al.

NATURE MEDICINE (2020)

Add to Collection
Review Hematology

The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy

Sarah L. Buchan et al.

BLOOD (2018)

Add to Collection
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.